Tolerability/PK study of MAT2203 in patients with a hematologic malignancy
Phase of Trial: Phase I
Latest Information Update: 16 May 2017
At a glance
- Drugs Amphotericin B (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions
- 16 May 2017 According to a Matinas BioPharma media release, this trial is expected to initiate in the third quarter of 2017.
- 28 Nov 2016 New trial record
- 15 Nov 2016 According to a Matinas BioPharma media release, company plans to initiate this study in H1 2017.